GeneDx Holdings Corp.
Rank #48HypergrowthWGS · Nasdaq · Healthcare
GeneDx Holdings Corp. (WGS) — Rank #48 by gross profitability (GP/assets 0.62) · ROE -8.6% · Piotroski F-Score 6 / 9.
As-of 2026-09-15 · CIK 0001818331 · all metrics point-in-time as of the filing date.
About
GeneDx Holdings Corp., a genomics company, provides genetic testing services.
Show moreShow less
The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp.
was founded in 2000 and is headquartered in Stamford, Connecticut.
- Industry
- Diagnostics & Research
- Sector
- Healthcare
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- genedx.com
Price History
Company Snapshot
P/S is the primary valuation lens — earnings are reinvested, not available for P/E.
Market Cap
$2.87B
P/E (annual)
—
P/S (annual)
6.7
P/B
11.8
P/OCF (annual)
86.3
Shareholder Yield
-6.5%
Employees
1,300
Industry
Diagnostics & Research
Exchange
Nasdaq
Signal Flags
Quality Profile
Profitability
1/1 passSafety
1/1 passCash Flow
3/3 passGrowth
1/2 passTerry Smith quality gate
Passes 1/5 Terry Smith thresholds2 of 5 thresholds not computable from filed data.
What Growth Is Priced In
Implied revenue growth (10Y)
39.5%
The annual FCF growth rate today's price requires over a 10-year horizon (discount rate 10%, terminal growth 2.5%).
Dilution drag: 6.5% — per-share value needs a total required return of 46.0% once share-count change is priced in.
vs. own 6-year median revenue growth: 18.3%
priced above its own historyCost-of-equity sensitivity (implied growth at different discount rates)
r = 8%
33.5%
r = 10% (base)
39.5%
r = 12%
44.7%
Net debt / market cap: -1.3%
Note: current FCF margin is 1.5σ above its historical mean — implied growth may understate valuation risk if the margin reverts.
Valuation History
Current multiple vs historical range at each filing date. Band spans 25th-75th percentile.
P / S
Price / revenue per share
P / B
Price / book value per share
P / GP
Price / gross profit per share
Earnings bubble check
Current margins may be above sustainable levels — a P/E based on peak earnings can overstate cheapness.
Disclosure regression check
A previously-disclosed line item is no longer reported. Worth checking the filing for why.
Revenue growth and the path to profitability (margin trend) are the primary reads at this stage.
Profitability
Gross profitability (GP / assets)
0.62
Primary signal (Novy-Marx).
2nd of 8 SIC 80 peers
Return on equity
-8.6%
Gross margin
69.7%
2nd of 8 SIC 80 peers
Revenue growth (YoY)
40.0%
Gross margin improving
Margin trend vs prior year.
Operating Leverage
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Revenue vs COGS | ||||
| Revenue vs OpEx | ||||
| Op. Income vs Revenue |
Growth
Revenue CAGR (3Y)
22.1%
Revenue CAGR (5Y)
19.0%
Earnings CAGR (3Y)
—
FCF CAGR (3Y)
—
Anti-fragile safety
Balance-sheet safety
Composite anti-fragile check.
Debt / equity
0.97
4th of 7 SIC 80 peers (best = lowest)
Current ratio
3.30×
3rd of 8 SIC 80 peers
Quick ratio
2.90×
Net cash
$35.71M
Cash & equivalents minus total debt.
Cash-flow health
Free cash flow
$14.26M
Operating cash flow minus capex.
Positive free cash flow
FCF / net income
1.68
Cash-backing of earnings.
FCF/NI divergence
Unfavorable divergence (yellow flag).
Accruals healthy
Cash-backed earnings.
SBC / revenue
7.5%
Stock-based comp intensity.
Piotroski F-Score
F-Score
6 / 9
Fundamental-strength score (0-9).